<DOC>
	<DOCNO>NCT00265837</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor bone marrow transplant peripheral blood stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When certain stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Removing T cell donor cell transplant may stop happen . PURPOSE : This randomized phase III trial study donor bone marrow treat laboratory use two different device compare well work treat patient undergo donor bone marrow transplant hematologic cancer .</brief_summary>
	<brief_title>Laboratory-Treated Donor Bone Marrow Treating Patients Who Are Undergoing Donor Bone Marrow Transplant Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effectiveness , term incidence graft failure incidence great grade 1 acute graft-vs-host disease , ex vivo manipulation bone marrow cell comprise counterflow centrifugal elutriation T-lymphocyte depletion follow CD34-positive stem cell selection use CliniMACS v Isolex 300i patient hematologic malignancy undergo allogeneic bone marrow transplantation HLA-identical sibling donor . OUTLINE : This randomize study . Patients stratified age ( &lt; 40 vs 40-65 ) disease status ( low-risk [ i.e. , chronic phase chronic myelogenous leukemia , acute myeloid leukemia first complete remission ( CR ) , acute lymphocytic leukemia first CR , Hodgkin 's non-Hodgkin 's lymphoma sensitive relapse , multiple myeloma CR partial remission ) vs high-risk [ i.e. , others ] ) . Patients randomize 1 2 treatment arm . - Arm I : Allogeneic bone marrow cell subject counterflow centrifugal elutriation ( CCE ) T-lymphocyte depletion . The elutriation fraction process 2-2.5 hour use CliniMACS select CD34-positive stem cell . - Arm II : Allogeneic bone marrow cell subject CCE T-lymphocyte depletion . The elutriation fraction process 4-4.5 hour use Isolex 300i select CD34-positive stem cell . Patients arm undergo ex vivo manipulate , T-lymphocyte-depleted , CD34-positive stem cell-selected , allogeneic bone marrow transplantation day 0 . After transplantation , patient follow periodically 1 year . PROJECTED ACCRUAL : A total 206 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy genetic disorder : Acute myeloid leukemia ( AML ) , meet 1 follow criterion Primary resistant disease Disease complete remission ( CR ) Disease first early relapse Secondary AML arise myelodysplastic syndrome Acute lymphocytic leukemia ( ALL ) , meet 1 follow criterion : Primary resistant disease Disease CR Disease first early relapse Chronic myelogenous leukemia Myelodysplastic syndrome ( MDS ) Chronic myelomonocytic leukemia Philadelphia chromosomenegative myeloproliferative disorder Multiple myeloma Hodgkin 's lymphoma NonHodgkin 's lymphoma Genetic disorder inborn error metabolism Planning allogeneic bone marrow transplantation Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medical Center Must HLAidentical sibling donor serologic molecular type HLA class I antigens molecular type HLA class II antigens PATIENT CHARACTERISTICS : Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy No prior red blood cell platelet transfusion donor Other Concurrent participation another clinical trial allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>